MA52973B1 - SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL TARTRATE SALT -1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL, PROCESS FOR THEIR PREPARATION AND METHODS OF THEIR USE FOR TREATMENT OF CANCERS - Google Patents

SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL TARTRATE SALT -1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL, PROCESS FOR THEIR PREPARATION AND METHODS OF THEIR USE FOR TREATMENT OF CANCERS

Info

Publication number
MA52973B1
MA52973B1 MA52973A MA52973A MA52973B1 MA 52973 B1 MA52973 B1 MA 52973B1 MA 52973 A MA52973 A MA 52973A MA 52973 A MA52973 A MA 52973A MA 52973 B1 MA52973 B1 MA 52973B1
Authority
MA
Morocco
Prior art keywords
methods
difluoropropan
fluoropropyl
azetidin
pyrido
Prior art date
Application number
MA52973A
Other languages
French (fr)
Other versions
MA52973A (en
Inventor
Francis Gosselin
Paroma Chakravarty
Hans Iding
Haiming Zhang
Jie Xu
Cheol Keun Chung
Kyle Clagg
Michael Dalziel
Alec Fettes
Ngiap-Kie Lim
Andrew Mcclory
Kartik Nagapudi
Sarah Robinson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority claimed from PCT/US2019/037492 external-priority patent/WO2019245974A1/en
Publication of MA52973A publication Critical patent/MA52973A/en
Publication of MA52973B1 publication Critical patent/MA52973B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des formes solides, des sels tels que le composé b et des formulations de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azétidin-3-yl)amino)phényl)-3-méthyl-1,3,4,9-tétrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, des procédés et la synthèse de ceux-ci et des méthodes d'utilisation de ceux-ci dans le traitement d'un cancer.The present invention relates to solid forms, salts such as compound b and formulations of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin- 3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, methods and synthesis thereof and methods of using them in the treatment of cancer.

MA52973A 2018-06-21 2019-06-17 SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL TARTRATE SALT -1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL, PROCESS FOR THEIR PREPARATION AND METHODS OF THEIR USE FOR TREATMENT OF CANCERS MA52973B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687930P 2018-06-21 2018-06-21
PCT/US2019/037492 WO2019245974A1 (en) 2018-06-21 2019-06-17 Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use

Publications (2)

Publication Number Publication Date
MA52973A MA52973A (en) 2021-04-28
MA52973B1 true MA52973B1 (en) 2023-08-31

Family

ID=73543352

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52973A MA52973B1 (en) 2018-06-21 2019-06-17 SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL TARTRATE SALT -1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL, PROCESS FOR THEIR PREPARATION AND METHODS OF THEIR USE FOR TREATMENT OF CANCERS

Country Status (2)

Country Link
AR (1) AR114974A1 (en)
MA (1) MA52973B1 (en)

Also Published As

Publication number Publication date
MA52973A (en) 2021-04-28
AR114974A1 (en) 2020-11-11

Similar Documents

Publication Publication Date Title
RU2471781C2 (en) Novel disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
MX2023006785A (en) Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fl.
MA37866B1 (en) Aza-indazole or diaza-indazole derivatives for the treatment of pain
TN2016000188A1 (en) 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS
MA41134A (en) 5-AMINO-6H-THIAZOLO [4,5-D] PYRIMIDINE-2,7-DIONE SUBSTITUTE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS
MA31311B1 (en) OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS AGONISTS OF SPHINGOSINE 1-PHOSPHATE (S1P)
MA51204B1 (en) Pharmaceutical forms comprising a plasma kallikrein inhibitor
MA34903B1 (en) AZAINDAZOLE OR DIAZAINDAZOLE DERIVATIVES AS MEDICAMENTS
MA46038B1 (en) Sulfonimidoylpurinone compounds substituted in the 7 position for the treatment and prophylaxis of viral infection
MA40111B1 (en) Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein
MA47447A (en) 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR CANCER TREATMENT
MA38227B1 (en) Novel bicyclic compounds and their use as antibacterial agents and ß-lactamase inhibitors
TN2014000147A1 (en) (4-PHENYLIMIDAZOL-2-YL) ETHYLAMINE DERIVATIVES USEFUL AS SODIUM CHANNEL MODULATORS
MA30232B1 (en) HYDANTOIN BASED KINASE INHIBITORS
MA33450B1 (en) Oxazin derivatives and used as basic inhibitors for the treatment of neurological disorders
JP2009530282A5 (en)
EA201791941A1 (en) BICYCLIC KETOSULPHONAMIDE CONNECTIONS
TN2015000547A1 (en) HETEROAROMATIC COMPOUNDS AND THEIR USE AS LIGANDS OF DOPAMINE D1
MA34308B1 (en) SUBSTITUTED TRIAZOLOPYRIDINES
MA38260B1 (en) Novel cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist activity and muscarinic m3 antagonist activity
MA33533B1 (en) Pharmaceutical formulations for the treatment of cancer and other diseases or disorders
MA44079B1 (en) Pharmaceutical compositions comprising a derivative of phenylaminopyrimidine
MA43913B1 (en) Positive allosteric modulators of the m1 muscarinic receptor
MA39186A1 (en) Derivatives of [1,2,4] triazolo [1,5-a] pyrimidine used as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
SA520420382B1 (en) Dopamine d1 receptor positive allosteric modulators